Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 18;15(7):1149-1156.
doi: 10.18240/ijo.2022.07.16. eCollection 2022.

Incidence of ocular manifestations in patients with graft versus host disease after allogeneic stem cell transplant in Riyadh, Saudi Arabia

Tariq Aldebasi  1   2   3 , Rabia Bashir  1   2   3 , Shiji Gangadharan  1   2   3 , Naila A Shaheen  2   3 , Basil Alhussain  1   2   3 , Tariq Almudhaiyan  1   2   3 , Bader Alahmari  2   3   4
Affiliations

Incidence of ocular manifestations in patients with graft versus host disease after allogeneic stem cell transplant in Riyadh, Saudi Arabia

Tariq Aldebasi et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate the incidence and severity of ocular graft versus host disease (oGVHD) in patients who underwent allogeneic stem cell transplant (SCT) in King Abdul-Aziz Medical City, Saudi Arabia.

Methods: This is a retrospective cohort study conducted in King Abdul Aziz Medical City on patients who underwent allogeneic hematopoietic cell transplant (allo-HCT) from 2010 to 2017. The ocular examination findings including visual acuity, meibomian gland dysfunction, corneal and conjunctival staining with severity, corneal scarring, tear film meniscus and breakup time, anterior and posterior segment examination findings, intraocular pressure, treatment given, punctual plugs used or not, and follow up response were collected.

Results: The five years cumulative incidence of oGVHD among post-transplant patients was 56.98% (95%CI 38.6%-71.7%). The potential risk factors assessed for developing ocular manifestation were age, gender, donor's age, donor gender mismatch CD3 and CD34 infusion, while none of the correlates were identified as statistically significant risk factors of developing ocular manifestation. However, the incidence was statistically significantly different between patients diagnosed with acute myelocytic leukemia and acute lymphocytic leukemia (P=0.038). The mean latent period to develop ocular symptoms was 20.5mo. All patients had variable degree of dry eyes. None of the patients developed any posterior segment complication.

Conclusion: The incidence of oGVHD is low in King Abdul-Aziz Medical City. This can be attributed to the preconditioning and immunosuppressive regime.

Keywords: allogenic stem cell transplant; dry eye; graft versus host disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Five years cumulative incidence of ocular manifestations in GVHD patients
GVHD: Graft versus host disease.
Figure 2
Figure 2. Incidence of ocular manifestations in GVHD patients by gender
GVHD: Graft versus host disease.
Figure 3
Figure 3. Incidence of ocular manifestations in GVHD patients by primary diagnosis (AML vs ALL)
GVHD: Graft versus host disease; AML: Acute myelocytic leukemia; ALL: Acute lymphocytic leukemia.
See this image and copyright information in PMC

References

    1. Niederwieser D, Baldomero H, Atsuta Y, et al. One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the worldwide network for blood and marrow transplantation (WBMT) Blood. 2019;134(Supplement_1):2035.
    1. Pavletic SZ, Martin PJ, Schultz KR, Lee SJ. The future of chronic graft-versus-host disease: introduction to the 2020 national institutes of health consensus development project reports. Transplant Cell Ther. 2021;27(6):448–451. - PubMed
    1. Hahn T, McCarthy PL, Jr, Hassebroek A, Bredeson C, Gajewski JL, Hale GA, Isola LM, Lazarus HM, Lee SJ, LeMaistre CF, Loberiza F, Maziarz RT, Rizzo JD, Joffe S, Parsons S, Majhail NS. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31(19):2437–2449. - PMC - PubMed
    1. Pellegrini M, Bernabei F, Barbato F, Arpinati M, Giannaccare G, Versura P, Bonifazi F. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation. Am J Ophthalmol. 2021;227:25–34. - PubMed
    1. Nair S, Vanathi M, Mahapatra M, Seth T, Kaur J, Velpandian T, Ravi A, Titiyal JS, Tandon R. Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients. Ocul Surf. 2018;16(3):352–367. - PubMed

LinkOut - more resources